You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 27, 2024

Claims for Patent: 6,319,506

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,319,506

Title:	Method for treating hypercalcemia
Abstract:	A method for treating hypoparathyroidism and/or hypocalcemia by local administration of a neurotoxin, such as a botulinum toxin, to a parathyroid gland, thereby reducing an inhibitory effect upon parathyroid hormone secretion. A method for treating hyperparathyroidism and/or hypercalcemia by local administration of a neurotoxin, such as a botulinum toxin, to a sympathetic ganglion which innervates a parathyroid hormone secreting parathyroid cell, thereby reducing a stimulatory effect upon parathyroid hormone secretion.
Inventor(s):	Donovan; Stephen (Capistrano Beach, CA)
Assignee:	Allergan, Sales, Inc. (Irvine, CA)
Application Number:	09/704,441
Patent Claims:	1. A method for treating hypercalcemia resulting from hyperparathyroidism, the method comprising the step of administration of a Clostridial neurotoxin to a sympathetic ganglion which innervates a parathyroid gland, thereby treating hypercalcemia resulting from hyperparathyroidism. 2. The method of claim 1, wherein the Clostridial neurotoxin is administered in an amount of between about 10.sup.-3 U/kg and about 35 U/kg. 3. The method of claim 1, wherein the Clostridial neurotoxin is a botulinum toxin. 4. The method of claim 3, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C.sub.1, D, E, F and G. 5. The method of claim 1, wherein the Clostridial neurotoxin is botulinum toxin type A. 6. A method for treating hypercalcemia, resulting from hyperparathyroidism, the method comprising the step of administration of a therapeutically effective amount of a botulinum toxin to a sympathetic ganglion which innervates a parathyroid gland, thereby treating hypercalcemia resulting from hyperparathyroidism. 7. The method of claim 6, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C.sub.1, D, E, F and G. 8. A method for treating hypercalcemia, resulting from hyperparathyroidism, the method comprising the step of local administration to a sympathetic ganglion which innervates a parathyroid cell of a therapeutically effective amount of a botulinum toxin, thereby decreasing a parathyroid hormone secretion from a parathyroid C cell and treating hypercalcemia resulting from hyperparathyroidism. 9. The method of claim 8, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C.sub.1, D, E, F and G. 10. The method of claim 8, wherein the botulinum toxin is botulinum toxin type A.

Details for Patent 6,319,506

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015	⤷ Try a Trial	2020-02-22
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.